DrugPatentWatch

DrugPatentWatch Archives

You are currently viewing the 2001 archives
Click here to return to the current data set

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: PENTASA

Summary for Tradename: PENTASA

Patents:2
Applicants:1
NDAs:1
Suppliers: see list5
drug
patent expirations by year for
 PENTASA

Pharmacology for Tradename: PENTASA

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate

Clinical Trials for: PENTASA

Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers
Status: Completed Condition: Healthy

Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis
Status: Recruiting Condition: Ulcerative Colitis

Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)
Status: Completed Condition: Colitis, Ulcerative; Recurrence

Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.
Status: Completed Condition: Ulcerative Colitis

The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
Status: Recruiting Condition: Irritable Bowel Syndrome

Predicting Response to Standardized Pediatric Colitis Therapy
Status: Recruiting Condition: Ulcerative Colitis

Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
Status: Completed Condition: Healthy

The Colitis Once Daily Asacol Study
Status: Completed Condition: Ulcerative Colitis

Canadian Active & Maintenance Modified Pentasa Study
Status: Completed Condition: Active Ulcerative Colitis; Remission of Ulcerative Colitis

Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine
Status: Completed Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Shire Labs
PENTASA
mesalamine
Capsule, Extended Release; Oral020049MAY 10, 1993RXYes4,496,553<disabled><disabled>
Shire Labs
PENTASA
mesalamine
Capsule, Extended Release; Oral020049MAY 10, 1993RXYes4,980,173<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc